LTRN.NASDAQLantern Pharma INC

Form 4: Lantern Pharma Insider Leslie Kreis and Related Entities Sell Shares in Multiple Transactions

Sentiment:

SEC Form 4

📋All filings for Lantern Pharma INC
🔒Login to Follow

Leslie Kreis, a director and 10% owner of Lantern Pharma, along with related entities including Bios Funds and BP Directors, sold shares of LTRN common stock in a series of transactions from February 27-29, 2024.

Summary

  • Leslie Kreis, a director and 10% owner of Lantern Pharma, and related entities have sold shares of Lantern Pharma (LTRN) common stock.
  • The sales occurred over three days: February 27, 28, and 29, 2024.
  • The transactions involved multiple entities including Bios Fund II NT, LP, Bios Fund II QP, LP, Bios Fund II, LP, and BP Directors, LP.
  • The sales prices ranged from $4.35 to $5.33 per share.
  • The weighted average sale prices were $4.40 on February 27, $4.85 on February 28, and $4.87 on February 29.
  • The filing indicates the number of shares beneficially owned following the reported transactions for each entity.
  • Leslie Kreis disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
  • This Form 4 is the first of two filings due to the SEC's limit of 10 reporting persons per form.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to insider selling, which can create uncertainty. However, without knowing the reasons for the sales, it's difficult to assess the full impact.

Negatives

  • The sales by a director and related entities could be interpreted negatively by the market.

Risks

  • Continued selling pressure from insiders could negatively impact the stock price.
  • The reasons for the sales are not disclosed, which could lead to speculation and uncertainty.

Industry Context

Insider sales are a common occurrence, but the market often scrutinizes them for signals about a company's prospects. It's important to consider the overall context of the company's performance and industry trends.

Stakeholder Impact

  • Shareholders may react to the insider selling, potentially impacting the stock price.
  • The sales could raise questions among employees about the company's future prospects.

Key Dates

DateDescription
02/27/2024Date of first reported transaction; sales at a weighted average price of $4.40.
02/28/2024Date of second reported transaction; sales at a weighted average price of $4.85.
02/29/2024Date of third reported transaction; sales at a weighted average price of $4.87; date of filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.